The coagulation system changes in patients with chronic heart failure;Krešėjimo sistemos pokyčiai sergant lėtiniu širdies nepakankamumu

Medicina

Volumn 46, Issue 9, 2010, Pages 642-647

  Mongirdiene, Aušra ^a,b   Kuršvietiene, Lolita ^b   Kašauskas, Arturas ^b  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^b LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

Author keywords

Chronic heart failure; Coagulation system; Endothelium; Fibrinogen; Platelets

Indexed keywords

EID: 78751652395     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina46090091     Document Type: Article

References (33)

1. Swedberg K, Cleland I, Dargie H, Drexler H, Follath F, Komanda M, et al. Lėtinio širdies nepakankamumo diagnostikos ir gydymo gairės. (Guidelines for the diagnosis and treatment of chronic heart failure.) Gydymo menas 2006;1:21-53.
2. Vasiliauskas D, Kavoliūnienė A, Jasiukevičienė L, Grižas V, Kviesulaitis V. Penkeriu{ogonek} metu{ogonek} išgyvenamumas sergant širdies nepakankamumu ir jo ryšys su rizikos veiksniais bei klinikiniais požymiais. (Five-year survival in patients with heart failure and its relations with the risk factors.) Lietuvos bendrosios praktikos gydytojas 2006;2:14-9.
3. Chin BS, Blann AD, Gibbs CR, Chung NA, Conway DG, Lip GY. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest 2003;33:941-8.
4. Cugno M, Mari D, Meroni PL, Gronda E, Vicari F, Frigerio M, et al. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. Br J Haematol 2004;126:85-92.
5. Jankowska EA, Ponikowski P, Piepoli ME, Banasiak W, Anker SD, Poole-Wilson PA. Autonomic imbalance and immune activation in chronic heart failure-pathophysiological links. Cardiovasc Res 2006;70:434-45.
6. Fildes JE, Shaw SM, Yonan M, Williams SG. The immune system and chronic heart failure: is the heart in control? J Am Coll Cardiol 2009;53(12):1013-20.
7. Vila V, Martinez-Sales V, Almenar L, Lazaro IS, Villa P, Reganon E. Inflammation, endothelial dysfunction and angiogenesis markers in chronic heart failure patients. Int J Cardiol 2008;130(2):276-7.
8. Sánchez-Lázaro IJ, Almenar L, Reganon E, Vila V, Martínez-Dolz L, Martínez-Sales V, et al. Inflammatory markers in stabile heart failure and their relationship with functional class. Int J Cardiol 2008;129(3):388-93.
9. Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P, et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 2003;33:648-56.
10. Urban A, Ulf D, Tomas L. Elevated D-dimer level is an independent risk factor for cardiovascular death in out-patients with symptoms compatible with heart failure. Thromb Haemost 2004;92:1250-8.
11. Chong AY, Freestone B, Patel J, Lim HS, Hughes E, Blann AD, et al. Endothelial activation, dysfunction and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 2006;97:671-5.
12. Chong AY, Freestone B, Lim HS, Kistorp C, Gustafsson F, Lip GY. Plasma von Willebrand factor and soluble E-selectin levels in stabile outpatients with systolic heart failure: the Fredericksburg heart failure study. Int J Cardiol 2007;119:80-2.
13. Gurbel PA, Bliden KP, Hayes KM, Tantry U. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2004;2(4):535-45.
14. Chin BS, Gibs ChR, Blan AD, Lip GY. Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for betablocker selection. Clin Sci 2003;105:507-12.
15. Horigome H, Murakami T, Isobe T, Nagasawa T, Matsui A. Soluble P-selectin and thrombomodulin-protein C-protein S pathway in cyanotic congenital heart disease with secondary erythrocytosis. Thromb Res 2003;112:223-7.
16. Chung I, Choudhurg A, Lip G. Platelet activation in acute, decompensated congestive heart failure. Thromb Res 2007; 120(5):709-13.
17. Stumpt Ch, Lehner Ch, Eskafi S, Roaz D, Yilmaz A, Ropers S, et al. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 2003; 5:629-37.
18. Chung I, Choudhury A, Lip GY. Platelet adhesion in congestive heart failure. Thromb Res 2008;121(6):885-8.
19. Ma L, Yang L, Chen TD. Influence of large amount of shengmai injection on blood coagulation in patients with chronic heart failure [in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2003;23:275-7.
20. Shafer A, Fraccarollo D, Hildemann S, Christ M, Eigenthaler M, Kobsar A, et al. Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. Thromb Haemost 2003;89:1024-30.
21. Khmelnickaya K, Shlyakhto EV, Sitnikova HY. Left ventricular aneurysm and endothelium-dependent hemostasis in patients with chronic heart failure. J Clin Lipid 2008;2(55): 395-6.
22. Kamilova U, Shoalimova Z, Jurayeva Sh, Avezov D, Kevarkov A. Interrelation of von Willebrand's factor with endothelial dysfunction in patients with chronic heart failure. Heart Lung Circ 2008;17S:S24-5.
23. White KA, Ford SH, Preston T, Parker JD, Clark AL. Fibrinogen synthesis is increased in cachectic patients with chronic heart failure. Int J Cardiol 2008;129(3):363-7.
24. Shlyakhto E, Khmelnitskaya K, Sitnikova M. Endotheliumdependent prothrombotic and fibrinolytic factors in patients with ischemic heart disease and chronic heart failure. Atherosclerosis 2009;10(2):e549.
25. Boman K, Jansson JH, Nilson T, Swedberg K, Cleland JG, Poole-Wilson P. Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or von Willebrand factor in chronic heart failure-a COMET substudy. Thromb Res 2010;125: e46-e50.
26. Rand ML, Lcung R, Packham MA. Platelet function assays. Transf Apher Sci 2003;28:307-17.
27. Malinin AI, O'Connor CM, Dzhanashvili AI, Sane DC, Serebruany VL. Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? Am Heart J 2003;145(3):397-403.
28. Topcuoglu C, Yilmaz FM, Sahin D, Aydogdu S, Yilmaz G, Saydam G, et al. Total-and lipid-associated sialic acid in serum and thrombocytes in patients with chronic heart failure. Clin Biochem 2010;43:447-9.
29. Ly HQ, Kirtane AJ, Murphy SA, Buros J, Cannon ChP, Braunwald E, et al. Association of platelet counts on presentation and clinical outcomes in ST-elevated myocardial infarction. Am J Cardiol 2006;98(6):761-3.
30. Yazici M, Aksakal E, Demircan S, Sahin M, Sugkan O. Is slow coronary flow related with inflammation and procoagulant state. Anat J Cardiol 2005;950:3-7.
31. Jekell A, Hossain A, Alehagen U, Dahlstrom U, Rosen A. Elevated circulating levels of thioredoxin and stress in CHF. Eur J Heart Fail 2004;6:883-90.
32. Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S. et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 2003;33:648-56.
33. Kizer JR, Bella JN, Palmieri V, Liu JE, Best LG, Lee ET, et al. Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS). Am Heart J 2008; 2(151):412-8.